| A genome-wide search for human type 1 diabetes susceptibility genes JL Davies, Y Kawaguchi, ST Bennett, JB Copeman, HJ Cordell, ... Nature 371 (6493), 130-136, 1994 | 1836 | 1994 |
| EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291 KS Thress, R Brant, TH Carr, S Dearden, S Jenkins, H Brown, T Hammett, ... Lung cancer 90 (3), 509-515, 2015 | 531 | 2015 |
| Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis A Kindmark, A Jawaid, CG Harbron, BJ Barratt, OF Bengtsson, ... The pharmacogenomics journal 8 (3), 186-195, 2008 | 402 | 2008 |
| Chromosome–specific microsatellite sets for fluorescence–based, semi–automated genome mapping PW Reed, JL Davies, JB Copeman, ST Bennett, SM Palmer, LE Pritchard, ... Nature genetics 7 (3), 390-395, 1994 | 399 | 1994 |
| Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non–small cell lung cancer S Jenkins, JCH Yang, SS Ramalingam, K Yu, S Patel, S Weston, R Hodge, ... Journal of Thoracic Oncology 12 (7), 1061-1070, 2017 | 282 | 2017 |
| High‐throughput SNP genotyping S Jenkins, N Gibson Comparative and Functional Genomics 3 (1), 57-66, 2002 | 166 | 2002 |
| Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial S Lheureux, MC Cristea, JP Bruce, S Garg, M Cabanero, ... The Lancet 397 (10271), 281-292, 2021 | 153 | 2021 |
| Tissue and plasma EGFR mutation analysis in the FLAURA trial: Osimertinib versus Comparator EGFR tyrosine kinase inhibitor as first-line treatment in patients with EGFR-mutated … JE Gray, I Okamoto, V Sriuranpong, J Vansteenkiste, F Imamura, JS Lee, ... Clinical cancer research 25 (22), 6644-6652, 2019 | 113 | 2019 |
| Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum‐pemetrexed for T790M mutation‐positive advanced non … VA Papadimitrakopoulou, JY Han, MJ Ahn, SS Ramalingam, A Delmonte, ... Cancer 126 (2), 373-380, 2020 | 104 | 2020 |
| Evidence for a type 1 diabetes susceptibility locus (IDDM10) on human chromosome 10p11–q11 P Reed, F Cucca, S Jenkins, M Merriman, A Wilson, P McKinney, E Bosi, ... Human molecular genetics 6 (7), 1011-1016, 1997 | 89 | 1997 |
| A novel allelic variant of the human TSG-6 gene encoding an amino acid difference in the CUB module: chromosomal localization, frequency analysis, modeling, and expression HA Nentwich, Z Mustafa, MS Rugg, BD Marsden, MR Cordell, ... Journal of Biological Chemistry 277 (18), 15354-15362, 2002 | 72 | 2002 |
| EGFR mutation analysis for prospective patient selection in two phase II registration studies of osimertinib S Jenkins, JCH Yang, PA Jänne, KS Thress, K Yu, R Hodge, S Weston, ... Journal of Thoracic Oncology 12 (8), 1247-1256, 2017 | 69 | 2017 |
| Sequence variants in the melatonin-related receptor gene (GPR50) associate with circulating triglyceride and HDL levels S Bhattacharyya, B Challis, J Keogh, C Montague, J Brennand, J Morten, ... Journal of lipid research 47 (4), 761-766, 2006 | 53 | 2006 |
| EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non … T John, H Akamatsu, A Delmonte, WC Su, JS Lee, GC Chang, X Huang, ... Lung Cancer 126, 133-138, 2018 | 44 | 2018 |
| A novel variant of the MHC‐linked hsp70, hsp70‐hom, is associated with rheumatoid arthritis SC Jenkins, RE March, RD Campbell, CM Milner Tissue antigens 56 (1), 38-44, 2000 | 39 | 2000 |
| MA08. 03 osimertinib vs platinum-pemetrexed for T790M-mutation positive advanced NSCLC (AURA3): plasma ctDNA analysis YL Wu, S Jenkins, S Ramalingam, JY Han, A Delmonte, TC Hsia, J Laskin, ... Journal of Thoracic Oncology 12 (1), S386, 2017 | 33 | 2017 |
| 134O_PR: Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (aNSCLC) S Jenkins, J Yang, S Ramalingam, K Yu, S Patel, S Weston, R Lawrance, ... Journal of Thoracic Oncology 11 (4), S153-S154, 2016 | 33 | 2016 |
| EGFR T790M mutation testing within the osimertinib AURA Phase I study S Dearden, H Brown, S Jenkins, KS Thress, M Cantarini, R Cole, ... Lung cancer 109, 9-13, 2017 | 25 | 2017 |
| A laboratory assessment of the antimicrobial effectiveness of glove washing and re-use in dental practice J Bagg, S Jenkins, GR Barker Journal of Hospital Infection 15 (1), 73-82, 1990 | 24 | 1990 |
| Levels of EGFR T790M in plasma DNA as a predictive biomarker for response to AZD9291, a mutant-selective EGFR kinase inhibitor K Thress, JC Yang, M Ahn, D Kim, S Kim, Y Ohe, D Planchard, R Brant, ... Annals of Oncology 25, iv446, 2014 | 14 | 2014 |
